Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential

International Journal of Cancer

Volumn 72, Issue 2, 1997, Pages 295-300

  Aogi, Kenjiro ^a   Nishiyama, Masahiko ^b   Kim, Ryungsa ^a   Hirabayashi, Naoki ^a   Toge, Tetsuya ^a   Mizutani, Akiko ^a   Okada, Kosuke ^b   Sumiyoshi, Hidetaka ^c   Fujiwara, Yasuhiro ^c   Yamakido, Michio ^c   Kusano, Toshihisa ^d   Andoh, Toshiwo ^e  

^a Research Institute for Radiation Biology and Medicine   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^d Hiroshima Women's College   (Japan)

^e SOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CEPHARANTHINE; COCLAURINE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN P; IRINOTECAN; METHOTREXATE; PEPLEOMYCIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CELL MEMBRANE POTENTIAL; COLONY FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; GENE EXPRESSION; LEUKEMIA CELL LINE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT; CAMPTOTHECIN; CELL MEMBRANE; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; TUMOR CELLS, CULTURED;

EID: 0030739278     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970717)72:2<295::AID-IJC16>3.0.CO;2-F     Document Type: Article

References (20)

1. ANDOH, T., ISHII, K., SUZUKI, Y., IKEGANI, Y., KUSUNOKI, Y., TAKEMOTO, Y. and OKADA, K., Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Nat. Acad. Sci. (Wash.), 84, 5565-5569 (1987).
2. AOGI, K., NISHIYAMA, M., HIRABAYASHI, N., TOGE, T., OKADA, K., KUSANO, T. and ANDOH, T., A new multidrug-resistant cell line induced by continuous exposure to CPT-11: mechanism(s) for its resistance. In: R.S. Rao, M.G. Deo, L.D. Sanghvi and I. Mittra (eds.), XVI Intenational Cancer Congress, pp. 47-51, Monduzzi Editore, Bologna (1994).
3. AOGI, K., NISHIYAMA, M., SAEKI, S., HIRABAYASHI, N. and TOGE, T., Biochemical modulation of doxorubicin using an isoprenoid derivative, N-1379: plasma-transmembrane potential as a target site. Int. J. Oncol., 7, 1395-1399 (1995).
4. FRICHE, E., DANKS, M.K., SCHMIDT, C.A. and BECK, W.T., Decreased DNA topoisomerase II in danorubicin-resistant Ehrlich-ascites-tumor cells. Cancer Res., 51, 4213-4218 (1991).
5. HASMANN, M., VALET, G.K., TAPIERO, H., TREVORROW, K. and LAMPIDIS, T.J., Membrane-potential differences between adriamycin-sensitive and -resistant cells as measured by flow cytometry. Biochem. Pharmacol., 38, 305-312 (1989).
6. KARTNER, N., EVERNDEN-PORELLE, D., BRADLEY, G. and LING, V., Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature (Lond.), 316, 820-823 (1985).
7. KUBOTA, K., KANZAWA, F., NISHIO, K., TAKEDA, Y., OHMORI, T., FUJIWARA, Y., TERASHIMA, Y. and SAIJO, N., Detection of topoisomerase-I-gene mutation in CPT-11-resistant lung-cancer cell line. Biochem. biophys. Res. Commun., 188, 571-577 (1992).
8. LAMPIDIS, T.J., SAVARAJ, N., VALET, G.K., TREVORROW, K., FOURCADE, A. and TAPIERO, H., Relationship of chemical charge of anti-cancer agents to increased accumulation and cytotoxicity in cardiac tumor cells. Relevance to multidrug resistance. In: H. Tapiero, J. Robert and T.J. Lampidis (eds.), Anti-cancer drugs, pp. 29-38, John Libbey, Paris (1989).
9. MADELAINE, I., PROST, S., NAUDIN, A., RIOU, G., LAVELLE, F. and RIOU, J.F., Sequential modifications of topoisomerase-I activity in a camptothecin-resistant cell line established by progressive adaptation. Biochem. Pharmacol., 45, 339-348 (1993).
10. NAGAOKA, S., KAWASAKI, S., KARINO, Y. SASAKI, K. and NAKANISHI, T. Modification of cellular efflux and cytotoxicity of adriamycin by biscoclaurin alkaloid in vitro. Europ. J. Cancer clin. Oncol., 23, 1297-1302 (1987).
11. NISHIYAMA, M., AOGI, K., SAEKI, S., KIM, R., KUROI, K., YAMAGUCHI, Y. and TOGE, T. A role for plasma-trans-membrane potential in doxorubicin-induced cytotoxicity. Anti-cancer Res., 12, 849-852 (1992).
12. NISHIYAMA, M., HORICHI, N., MAZOUZI, Z., BUNGO, M., FOURCADE, A., TRINCAL, G., LAMPIDIS, T.J., MATHE, G., SAIJO, N. and TAPIERO, H., Relationship between accumulation, intracellular metabolism and DNA damage of fiuoro-doxorubicin (ME2303) and its metabolite (M1) in multidrug-resistant K562 cells. J. Cell Pharmacol., 2, 104-111 (1991).
13. NOONAN, K.E., BECK, C., HOLZMAYER, T.A., CHIN, J.E., WUNDER, J.S., ANDRULIS, I.L., GAZDAR, A.F., WILLMAN, C.L., GRIFFITH, B., VON HOFF, D.D. and RONINSON, I.B., Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. nat. Acad. Sci. (Wash.), 87, 7160-7164 (1990).
14. SLICHENMYER, W.J., ROWINSKY, E.K., DONEHOWER, R.C. and KAUFMANN, S.H., The current status of camptothecin analogues as anti-tumor agents. J. nat. Cancer Inst., 85, 271-291 (1993).
15. SOEHNLEN, B., YOUNG, L. and LIU, R., Standard laboratory procedures for in vitro assay of human tumor stem cells. In: S.E. Salmon (eds.), Cloning of human tumor stem cells, pp. 331-338, Alan R. Liss, New York (1980).
16. SUGIMOTO, Y., TSUKAHARA, S., OH-HARA, T., ISOE, T. and TSURUO, T., Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res., 50, 6925-6930 (1990).
17. SUMIYOSHI, H., FUJIWARA, Y., OHUNE, T., YAMAOKA, N., TAMURA, K. and YAMAKIDO, M., High-performance-liquid-chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma. J. Chromatogr. B., 670, 309-316 (1995).
18. TAKAGI, E., KAWATSU, H., SHIMOKATA, K., NISHIYAMA, Y., KOJIMA, K. and YOSHIDA, S., Establishment and characterization of resistant cells to etoposide (VP-16) from a mouse breast-cancer cell line, FM3A. Jap. J. Cancer Res. (Gann), 79, 938-944 (1988).
19. TSURUO, T., IIDA-SAITO, H., KAWABATA, H., OH-HARA, T. HAMADA, H. and UTAKOJI, T., Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and isolated clones. Jap. J. Cancer Res. (Gann), 77, 682-692 (1986).
20. WOESSNER, R.D., ENG, W.K., HOFMANN, G.A., RIEMAN, D.J., MCCABE, F.L., HERTZBERG, R.P., MATTERN, M.R., TAN, K.B. and JOHNSON, R.K., Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase-I content. Oncol. Res., 4, 481-488 (1992).